Cargando…

Prognostic Implications of Portal Venous Circulating Tumor Cells in Resectable Pancreatic Cancer

Circulating tumor cells (CTCs) are a promising prognostic biomarker for cancers. However, the paucity of CTCs in peripheral blood in early-stage cancer is a major challenge. Our study aimed to investigate whether portal venous CTCs can be a biomarker for early recurrence and poor prognosis in pancre...

Descripción completa

Detalles Bibliográficos
Autores principales: Choi, Young Hoon, Hong, Tae Ho, Yoon, Seung Bae, Lee, In Seok, Lee, Myung Ah, Choi, Ho Joong, Choi, Moon Hyung, Jung, Eun Sun
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9219704/
https://www.ncbi.nlm.nih.gov/pubmed/35740311
http://dx.doi.org/10.3390/biomedicines10061289
_version_ 1784732181584674816
author Choi, Young Hoon
Hong, Tae Ho
Yoon, Seung Bae
Lee, In Seok
Lee, Myung Ah
Choi, Ho Joong
Choi, Moon Hyung
Jung, Eun Sun
author_facet Choi, Young Hoon
Hong, Tae Ho
Yoon, Seung Bae
Lee, In Seok
Lee, Myung Ah
Choi, Ho Joong
Choi, Moon Hyung
Jung, Eun Sun
author_sort Choi, Young Hoon
collection PubMed
description Circulating tumor cells (CTCs) are a promising prognostic biomarker for cancers. However, the paucity of CTCs in peripheral blood in early-stage cancer is a major challenge. Our study aimed to investigate whether portal venous CTCs can be a biomarker for early recurrence and poor prognosis in pancreatic cancer. Patients who underwent upfront curative surgery for resectable pancreatic cancer were consecutively enrolled in this prospective study. Intraoperatively, 7.5 mL of portal and peripheral blood was collected, and CTC detection and identification were performed using immunofluorescence staining. Peripheral blood CTC sampling was performed in 33 patients, of which portal vein CTC sampling was performed in 28. The median portal venous CTCs (2.5, interquartile ranges (IQR) 1–7.75) were significantly higher than the median peripheral venous CTCs (1, IQR 0–2, p < 0.001). Higher stage and regional lymph node metastasis were related with a larger number of CTCs (≥3) in portal venous blood. Patients with low portal venous CTCs (≤2) showed better overall (p = 0.002) and recurrence-free (p = 0.007) survival than those with high portal venous CTCs (≥3). If validated, portal CTCs can be used as a prognostic biomarker in patients with resectable pancreatic cancer.
format Online
Article
Text
id pubmed-9219704
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-92197042022-06-24 Prognostic Implications of Portal Venous Circulating Tumor Cells in Resectable Pancreatic Cancer Choi, Young Hoon Hong, Tae Ho Yoon, Seung Bae Lee, In Seok Lee, Myung Ah Choi, Ho Joong Choi, Moon Hyung Jung, Eun Sun Biomedicines Article Circulating tumor cells (CTCs) are a promising prognostic biomarker for cancers. However, the paucity of CTCs in peripheral blood in early-stage cancer is a major challenge. Our study aimed to investigate whether portal venous CTCs can be a biomarker for early recurrence and poor prognosis in pancreatic cancer. Patients who underwent upfront curative surgery for resectable pancreatic cancer were consecutively enrolled in this prospective study. Intraoperatively, 7.5 mL of portal and peripheral blood was collected, and CTC detection and identification were performed using immunofluorescence staining. Peripheral blood CTC sampling was performed in 33 patients, of which portal vein CTC sampling was performed in 28. The median portal venous CTCs (2.5, interquartile ranges (IQR) 1–7.75) were significantly higher than the median peripheral venous CTCs (1, IQR 0–2, p < 0.001). Higher stage and regional lymph node metastasis were related with a larger number of CTCs (≥3) in portal venous blood. Patients with low portal venous CTCs (≤2) showed better overall (p = 0.002) and recurrence-free (p = 0.007) survival than those with high portal venous CTCs (≥3). If validated, portal CTCs can be used as a prognostic biomarker in patients with resectable pancreatic cancer. MDPI 2022-05-31 /pmc/articles/PMC9219704/ /pubmed/35740311 http://dx.doi.org/10.3390/biomedicines10061289 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Choi, Young Hoon
Hong, Tae Ho
Yoon, Seung Bae
Lee, In Seok
Lee, Myung Ah
Choi, Ho Joong
Choi, Moon Hyung
Jung, Eun Sun
Prognostic Implications of Portal Venous Circulating Tumor Cells in Resectable Pancreatic Cancer
title Prognostic Implications of Portal Venous Circulating Tumor Cells in Resectable Pancreatic Cancer
title_full Prognostic Implications of Portal Venous Circulating Tumor Cells in Resectable Pancreatic Cancer
title_fullStr Prognostic Implications of Portal Venous Circulating Tumor Cells in Resectable Pancreatic Cancer
title_full_unstemmed Prognostic Implications of Portal Venous Circulating Tumor Cells in Resectable Pancreatic Cancer
title_short Prognostic Implications of Portal Venous Circulating Tumor Cells in Resectable Pancreatic Cancer
title_sort prognostic implications of portal venous circulating tumor cells in resectable pancreatic cancer
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9219704/
https://www.ncbi.nlm.nih.gov/pubmed/35740311
http://dx.doi.org/10.3390/biomedicines10061289
work_keys_str_mv AT choiyounghoon prognosticimplicationsofportalvenouscirculatingtumorcellsinresectablepancreaticcancer
AT hongtaeho prognosticimplicationsofportalvenouscirculatingtumorcellsinresectablepancreaticcancer
AT yoonseungbae prognosticimplicationsofportalvenouscirculatingtumorcellsinresectablepancreaticcancer
AT leeinseok prognosticimplicationsofportalvenouscirculatingtumorcellsinresectablepancreaticcancer
AT leemyungah prognosticimplicationsofportalvenouscirculatingtumorcellsinresectablepancreaticcancer
AT choihojoong prognosticimplicationsofportalvenouscirculatingtumorcellsinresectablepancreaticcancer
AT choimoonhyung prognosticimplicationsofportalvenouscirculatingtumorcellsinresectablepancreaticcancer
AT jungeunsun prognosticimplicationsofportalvenouscirculatingtumorcellsinresectablepancreaticcancer